Our approach
Small molecules. Extraordinary possibilities.
Advancing a strategy in proprietary peptides, molecular design and delivery innovation.
Company
From where we are to where we intend to go.
Adaptogenics Health Corp. is a public company pursuing a strategy centred on proprietary peptides, small molecules and technologies that improve their performance.
TodayWhere we intend to go
01
Public company listed on the CSE as ADPT
→Secure promising peptide assets through exclusive licensing
02
Experienced scientific and commercial leadership
→Design and optimize molecules, then test them experimentally
03
An existing nutrition and supplement business, which continues
→Improve stability, exposure and delivery
04
Evaluating potential GLP 1 companion product opportunities
→Build evidence and intellectual property that guide development
The right column describes our intent. It does not describe current capabilities, owned programs or expected results.
Areas of interest
Starting with real human needs.
These are initial areas of interest, not established clinical programs. Our ambition is broader than any single molecule or indication.
A.01
Strength and physical function
Weight loss medicines change the body. Preserving strength and physical function is an area we want to explore.
A.02
Mitochondrial function
Mitochondria power every cell. Supporting their function is a long term area of scientific interest.
A.03
Resolving inflammation
Inflammation is meant to switch off. We are exploring pathways that help it resolve.
Leadership
Where molecular science meets deal making.
Chief Executive Officer
Dr. J. David Warren
20+years in peptide science
17issued patents
53+publications and book chapters
More than two decades of experience in medicinal chemistry, peptide science and translational research. Adjunct Associate Professor of Research in Biochemistry and Biophysics at Weill Cornell Medicine and former Director of the Milstein Chemistry Core Facility.
Published mechanistic research on SS 31 (elamipretide). Not an Adaptogenics asset.
Full biography →President
Antoun Nabhan
US$2B+buy side healthcare transactions led
4product approvals associated
NasdaqIPO leadership at two companies
Healthcare executive and investor with close to two decades of experience. Led more than US$2 billion in buy side healthcare transactions associated with four product approvals: Kyprolis, Stivarga, Quinsair and Somryst.
Prior transactions and approvals were achieved elsewhere and are not Adaptogenics assets.
Full biography →Track record
Done it before, from founding to public markets.
Found
3
pharmaceutical companies cofounded, including Convivia and Incellico, both acquired
Build the science
17
issued patents, with 53+ publications and book chapters, held by Dr. Warren
Transact
US$2B+
in buy side healthcare transactions led, associated with four product approvals
Public markets
2
Nasdaq IPO processes with leadership roles, at Establishment Labs and Soleno Therapeutics
Achieved by our leaders at other organizations. These are not Adaptogenics results.
Scientific depth to choose and shape molecules. Commercial experience to build value around them.
Intelligence vision
Better molecules begin with better evidence.
We intend to connect molecular characteristics, biological activity, delivery performance and meaningful functional outcomes, so research decisions rest on connected evidence.
This is a direction we intend to build toward. It is not an operational data or AI platform, and the visual is illustrative only.
Select a node to explore.
News
Latest releases.
Adaptogenics Announces Strategy to Build Proprietary Peptide Assets and Delivery Technologies
Adaptogenics announced a strategy to build proprietary peptide and small molecule assets through molecular design, selective acquisitions and exclusive licensing. The strategy combines advanced delivery research, planned sourcing from qualified GMP manufacturers and independent quality testing, with an initial focus on metabolic health, muscle preservation and mitochondrial biology. Programs will be guided by measurable development milestones and opportunities to establish defensible intellectual property.
Adaptogenics Appoints Antoun Nabhan as President
Adaptogenics appointed Antoun Nabhan, J.D., as President, bringing nearly 20 years of healthcare investment, corporate finance and business development experience. He has led or advised on more than $2 billion in healthcare transactions and led two Nasdaq IPO processes, with previous roles at Oaktree Capital Management, Onyx Pharmaceuticals and Raptor Pharmaceuticals. Working alongside CEO Dr. J. David Warren, he will lead asset acquisitions, licensing partnerships and strategic collaborations.
Adaptogenics Acquires Nutritional Research Assets to Advance GLP-1 Companion Initiative
Adaptogenics acquired nutritional research assets developed by Berkwood Research to support its GLP-1 companion initiative, focused on muscle preservation, metabolic health and physical function during medical weight loss. The acquisition includes four research compositions and 36 ingredient evidence reviews, providing a foundation for product selection and further testing. Dr. Robert Bergia, formerly a leader in protein nutrition research at ADM, joins as Scientific Advisor. Effectiveness in patients receiving GLP-1 therapies remains to be established.
CSE: ADPT
Follow the build.
Company overview, official releases and records, as they are verified and issued.